Haemodialysis with prostacyclin (Epoprostenol) alone.
Dialysis with prostacyclin (Epoprostenol, PGI2) alone prevents platelet activation and endothelial cell stimulation but not the elevation of fibrinopeptide A (FPA), a sensitive marker of fibrin generation. The generation of FPA may explain why some patients develop clot in the dialysis circuit during PGI2-only dialysis. In combination with heparin, PGI2 augments the anticoagulant effect of the heparin as well as providing platelet protection.
D001792:Blood Platelets / Q000187:drug effects; D011464:Epoprostenol / Q000627:therapeutic use*; D006470:Hemorrhage / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006435:Renal Dialysis / Q000379:methods*; D013927:Thrombosis / Q000517:prevention & control
D006493:Heparin; D011464:Epoprostenol